Categories
Health Law Highlights

Wade’s Health Law Highlights for August 19, 2025

340B

  • HRSA launched a pilot program on August 1, 2025 that will change how drug manufacturers provide 340B discounts to safety net healthcare providers. Under the new rebate model, covered entities will pay full price for drugs upfront and receive rebates later, rather than receiving discounts at the time of purchase as traditionally done. The pilot program applies only to manufacturers with products on the Medicare Drug Price Negotiation Selected Drug List, which includes 23 drugs subject to pricing negotiations under the Inflation Reduction Act. Manufacturer applications are due September 15, 2025, with the program beginning January 1, 2026, and HRSA is accepting public comments through August 30, 2025. The initiative follows disputes between HRSA and manufacturers over rebate models, which resulted in multiple lawsuits after HRSA blocked manufacturer attempts to implement such systems without approval. Source: Healthcare Law Blog

Cybersecurity

Data Privacy & Breach

Emerging Tech

Employee Benefits

  • Healthcare employers face mounting regulatory compliance challenges following the 2025 Comprehensive Reform Act, which was signed into law on July 4, 2025. The Act adds complexity to existing requirements including Affordable Care Act compliance for variable-schedule employees, fiduciary oversight of retirement and health plans, and nondiscrimination testing under Code Sections 105(h) and 125. Healthcare organizations increasingly form health and welfare plan committees to manage fiduciary responsibilities and protect boards from litigation related to pharmacy benefit management agreements and excessive fees. Hospital mergers and acquisitions create additional risks when benefits integration is not properly reviewed, potentially resulting in unexpected liabilities from retiree medical plans, multiemployer pension withdrawal liability, or undocumented 403(b) plans. Employers using self-insured plans, flexible spending accounts, or health savings accounts must conduct annual nondiscrimination testing to avoid negative tax consequences for higher-earning participants. Source: Saul Ewing LLP

Fraud & Abuse

  • Texas Attorney General sued Eli Lilly, accusing the drugmaker of bribing medical providers to prescribe its medications. The lawsuit alleges the company engaged in kickback schemes to induce providers to prescribe its profitable drugs, including GLP-1 medications Mounjaro and Zepbound used for weight loss and diabetes treatment. The action follows a previous lawsuit against insulin manufacturers, including Lilly, over pricing practices with pharmacy benefit managers. Lilly denied the allegations, stating the claims stem from a corporate relator whose accusations have been dismissed by multiple courts and the federal government. Source: Reuters
  • Dr. Ajay Aggarwal agreed to pay $2,053,515 to settle allegations that he defrauded federal healthcare programs by billing for procedures he did not perform. The 63-year-old Houston anesthesiologist and pain medicine doctor allegedly billed Medicare and Workers’ Compensation programs for the surgical implantation of neurostimulator electrodes from November 2021 to March 2023. Instead of performing these invasive procedures that typically require operating rooms and pay thousands of dollars, Aggarwal allegedly provided patients with electro-acupuncture treatments that involved inserting monofilament wire a few millimeters into patients’ ears and taping neurostimulators behind the ear in his clinic. The investigation involved multiple agencies including the U.S. Postal Service Office of Inspector General, Department of Labor Office of Inspector General, and Department of Health and Human Services Office of Inspector General. The settlement resolves allegations only, with no determination of liability. Source: U.S. Attorney’s Office, Southern District of Texas

HIPAA Privacy Rule

Mergers & Acquisitions

OIG Advisory Opinion

Patient Harm

  • Hospitals failed to capture half of patient harm events that occurred among hospitalized Medicare patients, according to an Office of Inspector General review. The OIG traced harm events from a 2022 report and found that hospitals often applied narrow definitions of harm, with staff not considering many events to be harm or stating it was not standard practice to capture them. Of the harm events hospitals did capture, few were investigated and even fewer resulted in improvements for patient safety. The OIG recommends that the Agency for Healthcare Research and Quality (AHRQ) and CMS work with partners to align harm event definitions and create a patient harm taxonomy, that CMS ensure surveyors prioritize Medicare Quality Assurance and Performance Improvement requirements, and that CMS instruct Quality Improvement Organizations to help hospitals identify weaknesses in their incident reporting systems. Increased federal leadership is needed to drive progress in patient safety after nearly 20 years of high patient harm rates nationwide. Source: OIG Report

Physician Compensation

  • Physicians and hospitals are generating higher revenues by increasing workload rather than receiving better reimbursement rates. From the second quarter of 2023 to 2025, median net gain per employed physician rose 8% while median revenue per provider unit of work increased 12% for physicians, but median net patient revenue per provider work unit declined 7%. Support staffing levels dropped 13% over two years, creating potential obstacles for future growth. Hospital operating margins improved to 3% when including shared service costs and 6.6% without those allocations, driven primarily by outpatient revenue increases. The trends reflect ongoing Medicare reimbursement declines that force providers to complete more work to maintain income levels. Source: Fierce Healthcare

Telehealth

  • States are implementing permanent telehealth regulations to replace pandemic-era emergency rules as federal waivers approach expiration. The DEA and HHS extended telemedicine prescribing waivers through December 31, 2025, allowing providers to prescribe controlled substances via telehealth without prior in-person examinations. New York finalized rules in May 2025 requiring in-person medical evaluations before prescribing controlled substances through telemedicine, with exceptions for recent evaluations, temporary coverage, and emergency situations. States including California, Delaware, Florida, New Hampshire, and Texas have enacted or proposed legislation with varying approaches to telehealth prescribing requirements. The DEA proposed a special registration system in March 2023 that would establish three types of registrations for remote prescribing of controlled substances with enhanced verification and monitoring requirements. Source: Healthcare Law Blog
  • Telemedicine has become a cornerstone of mental health services, with telehealth services for mental health issues increasing 16 to 20 times during the first year of the COVID-19 pandemic according to RAND Corporation data. A nationwide poll by the American Psychiatric Association found that over half of Americans would choose telehealth for mental health needs, with more than one-third preferring it outright. AI-powered platforms from companies like Teladoc Health and IBM Corporation now enable predictive analytics for early intervention in conditions like anxiety and depression, while digital mental health counseling apps like Calm and SilverCloud Health provide 24/7 support through chatbots and virtual therapists. Pittsburgh-area clinics have reduced wait times for psychiatric evaluations by up to 40% through telemedicine implementation, though experts warn against over-reliance on virtual care for cases like schizophrenia. Federal legislation has bolstered telehealth reimbursement and cross-state licensing, but challenges remain around data privacy and equitable access for low-income populations. Source: WebProNews

Value-Based Arrangements

  • The American Medical Association has released guidance to help private practices navigate partnerships with “aggregator entities” that manage value-based care arrangements. These aggregators are specialized private companies that help physicians handle the complexities of value-based care without requiring practices to fully invest in the technical infrastructure themselves. The AMA resource addresses three core areas: evaluating aggregator business models, understanding physician considerations when working with aggregators, and planning for potential termination of these relationships. According to Dr. Alexander Sun from the AMA’s Professional Satisfaction and Practice Sustainability unit, the guidance helps practices determine whether aggregator partnerships align with their value-based care goals. The resource is part of the AMA’s broader Business of Medicine education program, which includes materials on revenue-cycle management and accountable care organizations. Source: American Medical Association